Carvedilol sulfate - Jiangsu HengRui Medicine

Drug Profile

Carvedilol sulfate - Jiangsu HengRui Medicine

Alternative Names: Carvedilol sulfate extended release - Jiangsu HengRui Medicine

Latest Information Update: 26 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antihypertensives; Carbazoles; Ethanolamines; Heart failure therapies; Ischaemic heart disorder therapies; Phenyl ethers; Propanolamines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha beta adrenergic receptor antagonists; Antioxidants; Beta-adrenergic receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Heart failure; Hypertension

Most Recent Events

  • 26 Feb 2016 No development reported - Phase-III for Heart failure in China (PO)
  • 26 Feb 2016 No development reported - Phase-III for Hypertension in China (PO)
  • 31 Dec 2013 Phase-III clinical trials in Heart failure in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top